TTC17 and breast cancer: Taken together, decreased TTC17 levels in BC promoted metastatic behaviors but sensitized the cancers to a panel of routine anticancer drugs, such as rapamycin and paclitaxel, as verified, providing a treatment opportunity for patients with TTC17-related molecular subtypes (Fig. S8).